Agenda

Our education program offers cutting-edge technical sessions, shedding light on the latest advancements in the pharma industry.

Featured Events & Activities

All session times are listed in Greenwich Mean Time (GMT). Find your personal viewing time on the World Clock.

Tracks

Selected filters:

  • Biotech: Large Molecules - Cell & Gene - ATMPs
Tue, 13 May
Wed, 14 May
1015 – 1045
Biotech: Large Molecules - Cell & Gene - ATMPs
David Phasey, 3P Innovation
1045 – 1115
Biotech: Large Molecules - Cell & Gene - ATMPs
Andreas Traube, Fraunhofer IPA
1115 – 1145
Biotech: Large Molecules - Cell & Gene - ATMPs
Marco Flori, Staubli Robotic UK
Dan Strange, Cellular Origins
Kevin Vela, Catapult Cell and Gene Therapy
1315 – 1345
Biotech: Large Molecules - Cell & Gene - ATMPs
Jon Halling, Catapult Cell and Gene Therapy
Alfred Penfold, PM Group
1345 – 1415
Biotech: Large Molecules - Cell & Gene - ATMPs
Michael Vrijs, Incyte Biosciences
1415 – 1445
Biotech: Large Molecules - Cell & Gene - ATMPs
Paul Osborne, BioPhorum
Stephanie Whitmore, Eli Lilly & Company
Aateka Sultana, Boehringer Ingelheim
1530 – 1600
Biotech: Large Molecules - Cell & Gene - ATMPs
Patrick Fowler, Pfizer
Eilis Kelly, J&J
1600 – 1630
Biotech: Large Molecules - Cell & Gene - ATMPs
Bianca Bohrer, PSM GmbH Topmedicare
Theresa Ladwig, Skan AG
1630 – 1700
Biotech: Large Molecules - Cell & Gene - ATMPs
Marina Ferrari, Chiesi Farmaceutici
Angelo Bernardis, MD, Wood Plc

Speaker Qualifications

Speakers selected to present at ISPE events are leading professionals in their fields. However, it may be necessary to make substitutions. Every possible effort will be made to substitute a speaker with comparable qualifications. Every precaution is taken to ensure accuracy. ISPE does not assume responsibility for information distributed or contained in these events, or for any opinion expressed.

Agenda Changes

Agenda is subject to change. Last minute changes due to functional, private, or organizational needs may be necessary. The event organizer accepts no liability for any additional costs caused by a change of the agenda.